Literature DB >> 7862414

Ocular vaso-occlusive disease in primary antiphospholipid syndrome.

C Castañón1, M C Amigo, J L Bañales, A Nava, P A Reyes.   

Abstract

PURPOSE: To evaluate the ocular involvement in patients with the primary antiphospholipid syndrome.
METHODS: The authors performed a cross-sectional ophthalmologic study of 17 patients with the primary antiphospholipid syndrome. Retinal fluorangiography was performed in 13 patients.
RESULTS: Visual symptoms were described by ten patients. Visual acuity was markedly decreased in five eyes. Conjunctival telangiectases and microaneurysms, in addition to single instances of bilateral episcleritis and limbal keratitis, were the anterior segment findings. Fundus abnormalities were present in 15 patients. Venous tortuosity was the most common finding but there were instances of optic disc edema, vitreous hemorrhages, cotton-wool spots, vitreous bands, serous detachment of the macula, and retinal capillary abnormalities. Fluorangiography showed vaso-occlusive retinopathy in six eyes (5 patients, 29%). Choriocapillary vessel occlusion was observed in two eyes (1 patient) and binocular reticular degeneration of pigmentary epithelium was present in another case.
CONCLUSION: The eye is frequently involved in the primary antiphospholipid syndrome, and serious ocular damage may occur. Detailed ophthalmologic evaluation is warranted in these patients.

Entities:  

Mesh:

Year:  1995        PMID: 7862414     DOI: 10.1016/s0161-6420(95)31028-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

1.  Ocular involvement in primary antiphospholipid syndrome. Ocular involvement in primary APS.

Authors:  F Y Demirci; R Küçükkaya; K Akarçay; N Kir; T Atamer; H Demirci; E Ongör
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

Review 2.  Looking into the eyes of patients with antiphospholipid syndrome.

Authors:  D Yehudai; Y Shoenfeld; E Toubi
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 3.  Neurologic manifestations of the antiphospholipid syndrome.

Authors:  D Tanne; S Hassin-Baer
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

4.  Hypercoagulable states in patients with retinal venous occlusion.

Authors:  A M Abu El-Asrar; A G Abdel Gader; S Al-Amro; A K Al-Momen
Journal:  Doc Ophthalmol       Date:  1998       Impact factor: 2.379

Review 5.  Optic neuropathy in the "primary" antiphospholipid syndrome: report of a case and review of the literature.

Authors:  S Reino; F J Muñoz-Rodriguez; R Cervera; G Espinosa; J Font; M Ingelmo
Journal:  Clin Rheumatol       Date:  1997-11       Impact factor: 2.980

Review 6.  Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion.

Authors:  Yi Tang; Yan Cheng; Shuo Wang; Yongjie Wang; Pengjia Liu; Hong Wu
Journal:  Front Med (Lausanne)       Date:  2022-06-15

Review 7.  Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome.

Authors:  Sonja Praprotnik; Dusan Ferluga; Alenka Vizjak; Anastazija Hvala; Tadej Avcin; Blaz Rozman
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

8.  Primary antiphospholipid syndrome unusual presentation in a seventy two year old man.

Authors:  A Ajaj; E Luhishi; E Metaraiah
Journal:  Libyan J Med       Date:  2008-06-01       Impact factor: 1.657

9.  Retinal vein occlusion in two patients with primary antiphospholipid syndrome.

Authors:  J K Kim; M Y Kim; H S Yu; H K Jong; I S Hwang; C W Lee
Journal:  Korean J Intern Med       Date:  2001-12       Impact factor: 2.884

10.  Ocular Manifestations in Colombian Patients with Systemic Rheumatologic Diseases.

Authors:  Pilar Uribe-Reina; Juliana Muñoz-Ortiz; Carlos Cifuentes-González; Juliana Reyes-Guanes; Juan Pablo Terreros-Dorado; William Zambrano-Romero; Carolina López-Rojas; Fabien Mantilla-Sylvain; Rubén Darío Mantilla-Hernández; Alejandra de-la-Torre
Journal:  Clin Ophthalmol       Date:  2021-06-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.